[Skip to Navigation]
Invited Commentary
April 2017

Individualized Treatment of Laryngeal Cancer

Author Affiliations
  • 1Departments of Otolaryngology and Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 2Department of Oral and Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania
  • 3Eye and Ear Institute, Pittsburgh, Pennsylvania
JAMA Otolaryngol Head Neck Surg. 2017;143(4):367. doi:10.1001/jamaoto.2016.4298

In this issue of JAMA Otolaryngology–Head & Neck Surgery, Wolf et al1 describe very high survival rates in an unselected cohort of 247 patients with advanced laryngeal cancer. These patients were treated with a program of individualized bioselection. All of us invested in the care of patients with advanced laryngeal cancer must breathe a deep sigh of relief. Only 10 years ago, Hoffman et al,2 in a landmark review of the national cancer database, evaluated the outcome of 158 426 patients with laryngeal cancer. Between the years of 1985 and 2001, the survival rate had gone down. So what has changed?

Add or change institution